NEW YORK (GenomeWeb News) – Cepheid has hired Michael Bates to be VP of oncology research and development. Bates will be responsible for the company's microRNA program and the development and preclinical evaluation of its oncology testing portfolio.
Bates formerly was VP of clinical research at Monogram Biosciences, which was bought by LabCorp in 2009, where he was responsible for clinical research strategy and running the firm's oncology and virology programs.
Helicos Biosciences said this week that Elisabeth Allison and Robert Higgins have resigned from the firm's board of directors. The single-molecule sequencing technology developer said that their departures were not caused by any disagreement with the company related to operations, policies, or practices.
PharmaDiagnostics has named Sylviane Boucharens to be director of assay development. Boucharens formerly was head of a global compound repository and in vitro screening at Merck MSD's site in Newhouse, Scotland. Before that, she worked in the Immunology Department for Laboratoires Fournier.
The Biotechnology and Biological Sciences Research Council and the Institute for Animal Health (IAH) have appointed John Fazakerley to serve as IAH's new director, starting in June. Fazakerley currently is group leader and a professor of virology at The Roslin Institute in BBSRC's College of Medicine and Veterinary Medicine at the University of Edinburgh. He will take over the position for David Paton, who has been serving as interim director since Martin Shirley retired from the post.
IntegenX said this week that it has appointed Dennis Harris to be the company's chief scientific officer. Harris is a co-founder of IntegenX and has served on the company's board of directors since 2003. He served as CSO of Millipore until December 2010, when the company was acquired by Merck KGaA. Prior to that, he was vice president and CSO at Serologicals, which Millipore acquired in 2006.
Thomas Gallagher has stepped down from his positions as president, COO, and general counsel of Health Discovery Corporation to pursue a new opportunity. The company said this week that Gallagher will soon begin discussions with its board of directors to potentially start a new company that would use a non-exclusive license to HDC's patent portfolio in exchange for a minority ownership stake in the new venture.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.